Orlistat and Contrave are both oral medicines considered in weight management, but the apparent similarity in route conceals very different pharmacology and medical restrictions. Orlistat inhibits gastrointestinal lipases and reduces absorption of some dietary fat. Contrave is a specific extended-release combination of naltrexone and bupropion that acts through central nervous system pathways involved in appetite and reward. The fixed-dose formulation has its own FDA approval, warnings and administration requirements.
This page compares approved Contrave with orlistat rather than evaluating arbitrary separate prescriptions for bupropion and naltrexone. Buying two unrelated single-ingredient medicines is not automatically equivalent to receiving the approved extended-release Contrave formulation. The comparison therefore focuses on the named obesity product and its labeled risks, not an improvised combination of individual medicines.
OrliLab offers educational product comparisons and may receive appropriately disclosed affiliate revenue; it does not prescribe or dispense medicines. A prescription weight-management drug should not be selected only because it is oral or because an advertisement calls it convenient. Review indications, prior medications, potential contraindications, adherence and the actual pharmacy offer with a licensed clinician.
Orlistat and Contrave differ both in the part of the body where their primary effects arise and in their U.S. access rules. The OTC availability of Alli 60 mg does not extend to Contrave, and the availability of prescription 120 mg orlistat does not make the two drugs interchangeable.
The table uses the approved fixed-dose Contrave product rather than calling all bupropion/naltrexone combinations the same medication. This difference matters for both evidence interpretation and safe dispensing.
| Issue | Orlistat | Contrave |
|---|---|---|
| Active ingredient(s) | Orlistat | Naltrexone and bupropion ER |
| Principal pathway | Gastrointestinal lipase inhibition | Central appetite/reward-related pathways |
| Dosage form | Capsules | Fixed-dose extended-release tablets |
| U.S. access | 60 mg OTC; 120 mg Rx | Prescription only |
| Notable warning | GI issues, vitamins, interacting drugs and kidney risk | Boxed warning: suicidal thoughts and behaviors |
| Special clinical issue | Fat-containing meals and nutrient absorption | Opioid use, seizure risk, blood pressure and psychiatric history |
Contrave has U.S. prescription labeling for long-term body-weight reduction and maintenance in eligible adults when used with reduced-calorie eating and physical activity. Orlistat’s OTC and prescription products have separate labeled conditions and patient eligibility rules. A person’s approved product options depend on medical history and the actual label.
If the intent is to understand products available without a prescription, the OTC orlistat guide is the appropriate next read; Contrave is not an OTC substitute for Alli.
Orlistat reduces the breakdown of dietary fat within the gastrointestinal tract, which explains both its meal-related use and common oily gastrointestinal effects. Contrave combines naltrexone, an opioid antagonist, with bupropion, a drug with effects on norepinephrine and dopamine-related pathways. Its appetite-related effects are therefore mechanistically distinct.
The mechanism alone does not predict effectiveness or suitability for a particular person. Orlistat mechanism discusses fat digestion; Contrave’s product-specific evidence must be assessed within its FDA label rather than extrapolated from studies of its individual components.
Contrave was evaluated in randomized, placebo-controlled weight-management studies lasting up to 56 weeks, with dietary and physical-activity counseling provided as part of the trial programs. Its U.S. labeling reports outcomes against its own placebo groups, including the proportion reaching at least 5% body-weight loss. Prescription orlistat has a separate clinical-trial program. Their study populations, behavioral interventions, treatment durations and missing-data methods differ, so the percentages do not constitute a direct Contrave-versus-orlistat trial.
For Contrave, distinguish trials of the approved fixed-dose extended-release formulation from studies of bupropion or naltrexone alone. Orlistat efficacy evidence provides the ingredient-specific foundation without making claims of guaranteed response.
Contrave carries an FDA boxed warning about suicidal thoughts and behaviors associated with antidepressant-containing products in children, adolescents and young adults. The warning calls for monitoring for worsening depression, suicidal thoughts and unusual behavioral changes. Contrave is not approved as a treatment for depression and is not approved for pediatric use. These qualifications matter when comparing a centrally acting prescription medicine with orlistat, which has a different safety profile.
A brief shopping comparison must not reduce this to “possible mood changes.” The prescriber should review personal psychiatric history, existing medicines and any concerning symptoms. In contrast, orlistat’s major warnings arise from its own interaction and absorption profile.
Contrave is contraindicated with chronic opioid use, including opioid agonist or partial-agonist treatment, and in acute opioid withdrawal. Its label also names seizure disorders, uncontrolled hypertension, bulimia or anorexia nervosa, use of another bupropion-containing product and certain abrupt drug or alcohol withdrawal situations as contraindications. A prescriber must also review monoamine oxidase inhibitors and other potential interactions. These restrictions differ materially from orlistat’s contraindications and intestinal-absorption interactions.
Patients should disclose opioid pain medicines, substance-use treatment, seizure history, eating disorders and other prescribed drugs to the clinician. Orlistat interactions separately explains issues such as absorption and other drug-specific monitoring.
Contrave is not a collection of conventional immediate-release tablets that users can divide or assemble on their own. The approved product is extended release and requires prescriber-directed titration and administration. Crushing or substituting components would undermine the product-based comparison and may create safety risks.
Orlistat follows a meal-linked dosing framework, and its use may be affected by how much dietary fat a meal contains. A consumer should follow the relevant label rather than assume all weight-management pills are taken in the same way.
Orlistat’s familiar tolerability pattern involves oily stools, gas with discharge and bowel urgency, with additional considerations for vitamins and rare kidney problems. Contrave may cause nausea, constipation, headache and other effects, alongside more consequential labeling about psychiatric changes, seizures and opioid antagonism.
Neither can be characterized as safer for all patients. The appropriate clinical discussion should include medicine history, blood pressure, mood symptoms, bowel health and planned pregnancy. Orlistat side effects offers more detail without overshadowing Contrave’s boxed warning.
An OTC orlistat package is purchased through a different payment pathway from prescription Contrave, and prescription orlistat may have separate cash or insurance costs. Branded product price and available benefits can change, so an isolated coupon banner does not provide a reliable cross-product comparison.
For the prescription brand, use Contrave buying and pharmacy access to review legal access. Orlistat pricing factors addresses how OTC quantities and 120 mg prescription costs should be compared.
The fact that Contrave contains two known active ingredients does not justify reproducing its dosing by combining prescriptions intended for different conditions. Formulation, release properties, labeling, interaction risks and clinical studies refer to the approved combination product.
If a prescriber evaluates another regimen, that is a separate medical decision; no online buying guide should present an improvised drug combination as a verified generic substitute. This page therefore keeps its brand-specific angle rather than duplicating a formulation or ingredient discussion.
Confirm the intended approved indication, contraindications, prescribed product name, current medicines including opioids, monitoring needs and expected costs. Ask how weight response and safety will be reassessed rather than chasing a guaranteed result or an apparent discount.
For another branded combination, orlistat versus Qsymia compares a different drug pair and its own safety program. Orlistat buying options covers legal OTC and prescription purchasing routes.
No. Contrave contains naltrexone and bupropion in a fixed-dose extended-release tablet; orlistat inhibits gastrointestinal lipases.
No. Contrave is a prescription-only fixed-dose naltrexone/bupropion extended-release product in the United States. OTC Alli 60 mg is a different medicine with a separate Drug Facts label and eligibility requirements.
Yes. The boxed warning concerns suicidal thoughts and behaviors associated with antidepressant medicines, particularly in younger populations. Patients should discuss changes in mood or behavior with their clinician; Contrave is not approved for children.
Chronic opioid use, including opioid agonist or partial-agonist treatment, and acute opioid withdrawal are contraindications to Contrave. A clinician needs to review current and recent opioids before any prescribing decision; patients must not independently stop opioid treatment.
No. Separate prescriptions should not be assumed equivalent to the approved fixed-dose extended-release formulation.
No. Orlistat primarily reduces absorption of dietary fat; Contrave acts through central pathways related to appetite and reward.
No. Contrave is approved for eligible adults, not pediatric patients. Its boxed warning also requires attention to suicidal thoughts and behaviors; age and psychiatric history are relevant to prescribing discussions.
No. Contrave and orlistat have separate randomized trials with different populations, comparators, duration and lifestyle interventions. Their weight-loss percentages cannot be treated as a head-to-head result or an individualized prediction.
Discuss psychiatric and seizure history, opioid medicines, uncontrolled blood pressure, eating disorders and other bupropion-containing prescriptions. These are label-specific risks that differ from orlistat’s gastrointestinal, vitamin-absorption and interaction profile.
The exact label, contraindications, clinical history, tolerability, treatment routine and legal access should be reviewed with a clinician.